COSCIENS Biopharma (TSE:CSCI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
COSCIENS Biopharma Inc. has announced the appointment of Pierre Labbé as a new director and the Chair of the Audit Committee, succeeding Dennis Turpin who resigned. Labbé, with over 30 years in financial leadership, including roles at Fonds QScale S.E.C. and IMV Inc., brings vast experience in finance, M&A, and strategic planning to COSCIENS, a company known for developing a broad range of pharmaceutical and cosmeceutical products.
For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.